Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis

Journal of Vascular Access

Volumn 9, Issue 2, 2008, Pages 142-147

  Trimarchi, Hernán ^a   Duboscq, C ^a   Genoud, V ^b   Lombi, F ^a   Muryan, A ^a   Young, P ^a   Schwab, M ^c   Castanon M ^b   Rodriguez Reimundes E ^a   Forrester, M ^a   Pereyra, H ^a   Campolo Girard, V ^a   Seminario, O ^a   Alonso, M ^a   Kordich, L ^b  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

4G 5G polymorphism; C reactive protein; Endothelium; Hemodialysis; Plasminogen activator inhibitor 1; Thrombosis

Indexed keywords

C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLITEF;

AGED; ARTERIOVENOUS SHUNT; ARTICLE; BLOOD VESSEL CATHETERIZATION; BLOOD VESSEL GRAFT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; OBSERVATIONAL STUDY; POLITEF IMPLANT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOSIS; VASCULAR ACCESS;

EID: 49649104988     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980800900212     Document Type: Article

References (31)

1. Molino D, De Lucia D, Marotta R, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68: 1223-9.
2. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that CRP is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-21.
3. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker A, Stehouwer CDA. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-8.
4. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
5. Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE. The relationship between plasma t-PA and API levels is dependent on epistatic effects of the ACE I/D and PAI 4G/5G polymorphism. Clin Gen 2002; 62: 53-9.
6. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-6.
7. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: 209-20.
8. Sitko A, Hervio L, Loskutoff D. Plasminogen activator inhibitors. In: Colman R ed. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2001; 355-64.
9. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003; 10: 541-4.
10. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58: 2425-36.
11. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 1996; 7: 2578-89.
12. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1993; 142: 59-70.
13. Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002; 39: 695-705.
14. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: Evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
15. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790-5.
16. Devaraj S, Xu DY, Jialal I. C-reactive protein increases PAI-1 expression and activity in HAEC: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
17. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anion up regulate PAI expression by induction of NFB-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-80.
18. Ando R, Doi M, Yamauchi K, et al. Association of beta fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels and no association of PAI polymorphism with plasma PAI levels in hemodialysis patients. Clin Nephrol 2002; 58: 25-32.
19. Aucella F, Margaglione M, Vigilante M, et al. PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant 2003; 18: 1142-6.
20. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
21. Lund LR, Riccio A, Andreasen PA, et al. Transforming growth factor-beta is a strong and phase actino positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. Embo J 1987; 6: 1281-6.
22. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor in vivo. Tissue specificity and induction by lipopolysaccharide, TNF-alpha and TGF-beta. J Clin Invest 1991; 88: 1346-53.
23. Olofsson B, Korpelainen E, Peppeer MS, et al. VEGF-beta binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
24. Dichtl W, Stiko A, Eriksson P, et al. Oxidized LDL and lysophosphatidilcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 3025-32.
25. Cheng JJ, Chao YJ, Wung BS, Wang DL. Cyclic strain-induced PAI-1 released from endothelial cells involves reactive oxygen species. Biochem Biophys Res Commun 1996; 225: 100-5.
26. Zidovetzki R, Wang JL, Kim JA, Chen P, Fisher M, Hofman FM. Endothelin-1 enhances PAI-1 production by human brain endothelial cells vis protein kinase-C dependent pathway. Arterioscler Thromb Vasc Biol 1999; 19: 1768-75.
27. Zhao W, Spitz DR, Oberley LW, Robbins ME. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res 2001; 61: 5537-43.
28. Venugopal SK, Devaraj S, Jialal I. CRP decreases prostacyclin release from HAEC. Circulation 2003; 108: 1676-8.
29. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in HAEC. Circulation 2002; 106: 1439-41.
30. Balnn AD, Lip GY. Efects of CRP on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from HUVEC. Blood Coagul Fibrinolysis 2003; 14: 335-40.
31. Genoud V, Castañon M, Kordich L. Prevalencia del polimorfismo 4G/5G del inhibidor del activador del plasminogeno PAI-1 4G/5G) en Argentina Act Bioquím. Clin Latinoam 2006; 5 (suppl 5): 71.